Literature DB >> 2614686

The influence of assay variability on pharmacokinetic parameter estimation.

D A Graves1, C S Locke, K T Muir, R P Miller.   

Abstract

The impact of assay variability on pharmacokinetic modeling was investigated. Simulated replications (150) of three "individuals" resulted in 450 data sets. A one-compartment model with first-order absorption was simulated. Random assay errors of 10, 20, or 30% were introduced and the ratio of absorption rate (Ka) to elimination rate (Ke) constants was 2, 10, or 20. The analyst was blinded as to the rate constants chosen for the simulations. Parameter estimates from the sequential method (Ke estimated with log-linear regression followed by estimation of Ka) and nonlinear regression with various weighting schemes were compared. NONMEM was run on the 9 data sets as well. Assay error caused a sizable number of curves to have apparent multicompartmental distribution or complex absorption kinetic characteristics. Routinely tabulated parameters (maximum concentration, area under the curve, and, to a lesser extent, mean residence time) were consistently overestimated as assay error increased. When Ka/Ke = 2, all methods except NONMEM underestimated Ke, overestimated Ka, and overestimated apparent volume of distribution. These significant biases increased with the magnitude of assay error. With improper weighting, nonlinear regression significantly overestimated Ke when Ka/Ke = 20. In general, however, the sequential approach was most biased and least precise. Although no interindividual variability was included in the simulations, estimation error caused large standard deviations to be associated with derived parameters, which would be interpreted as interindividual error in a nonsimulation environment. NONMEM, however, acceptably estimated all parameters and variabilities. Routinely applied pharmacokinetic estimation methods do not consistently provide unbiased answers. In the specific case of extended-release drug formulations, there is clearly a possibility that certain estimation methods yield Ka and relative bioavailability estimates that would be imprecise and biased.

Mesh:

Year:  1989        PMID: 2614686     DOI: 10.1007/bf01071350

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  20 in total

1.  KINETIC ANALYSIS OF BLOOD LEVELS AND URINARY EXCRETION IN THE ABSORPTIVE PHASE AFTER SINGLE DOSES OF DRUG.

Authors:  J G WAGNER; E NELSON
Journal:  J Pharm Sci       Date:  1964-11       Impact factor: 3.534

2.  Per cent absorbed time plots derived from blood level and/or urinary excretion data.

Authors:  J G WAGNER; E NELSON
Journal:  J Pharm Sci       Date:  1963-06       Impact factor: 3.534

3.  Estimation of theophylline absorption rate by means of the Wagner-Nelson equation.

Authors:  J G Wagner
Journal:  J Allergy Clin Immunol       Date:  1986-10       Impact factor: 10.793

4.  An evaluation of population pharmacokinetics in therapeutic trials. Part II. Detection of a drug-drug interaction.

Authors:  T H Grasela; E J Antal; L Ereshefsky; B G Wells; R L Evans; R B Smith
Journal:  Clin Pharmacol Ther       Date:  1987-10       Impact factor: 6.875

5.  Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1983-06

Review 6.  Estimation of the individual metabolic state and its consideration in optimal pharmacotherapy.

Authors:  W Riess; S Brechbühler; P H Degen; W Dieterle; G Dörhöfer; K F Feldmann
Journal:  Int J Clin Pharmacol Res       Date:  1983

7.  Extended least squares nonlinear regression: a possible solution to the "choice of weights" problem in analysis of individual pharmacokinetic data.

Authors:  C C Peck; S L Beal; L B Sheiner; A I Nichols
Journal:  J Pharmacokinet Biopharm       Date:  1984-10

8.  Greatly enhanced bioavailability of theophylline on postprandial administration of a sustained release tablet.

Authors:  M Lagas; J H Jonkman
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

9.  Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1981-10

10.  Pharmacokinetics of ordinary and sustained-release lithium carbonate in manic patients after acute dosage.

Authors:  D P Thornhill
Journal:  Eur J Clin Pharmacol       Date:  1978-12-01       Impact factor: 2.953

View more
  10 in total

1.  Analysis of animal pharmacokinetic data: performance of the one point per animal design.

Authors:  E I Ette; A W Kelman; C A Howie; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1995-12

2.  Evaluation of pharmacokinetic studies: is it useful to take into account concentrations below the limit of quantification?

Authors:  H Humbert; M D Cabiac; J Barradas; C Gerbeau
Journal:  Pharm Res       Date:  1996-06       Impact factor: 4.200

3.  On the recording of sample times and parameter estimation from repeated measures pharmacokinetic data.

Authors:  H Sun; E I Ette; T M Ludden
Journal:  J Pharmacokinet Biopharm       Date:  1996-12

4.  Application of NONMEM to routine bioavailability data.

Authors:  D A Graves; I Chang
Journal:  J Pharmacokinet Biopharm       Date:  1990-04

5.  Application of optimal sampling theory to the determination of metacycline pharmacokinetic parameters: effect of model misspecification.

Authors:  M Tod; C Padoin; K Louchahi; B Moreau-Tod; O Petitjean; G Perret
Journal:  J Pharmacokinet Biopharm       Date:  1994-04

6.  Antibiotics in Adult Cystic Fibrosis Patients: A Review of Population Pharmacokinetic Analyses.

Authors:  Mehdi El Hassani; Jean-Alexandre Caissy; Amélie Marsot
Journal:  Clin Pharmacokinet       Date:  2021-01-15       Impact factor: 6.447

7.  Population pharmacokinetic modeling of steady state carbamazepine clearance in children, adolescents, and adults.

Authors:  D M Reith; W D Hooper; J Parke; B Charles
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-02       Impact factor: 2.745

8.  Effect of various exposure scenarios on the biological monitoring of organic solvents in alveolar air. I. Toluene and m-xylene.

Authors:  S Laparé; R Tardif; J Brodeur
Journal:  Int Arch Occup Environ Health       Date:  1993       Impact factor: 3.015

9.  Quality of pharmacokinetic research in oncology.

Authors:  J Siderov; J E Brien; D J Morgan; J Zalcberg; W Cosolo
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

10.  Approaches to handling missing or "problematic" pharmacology data: Pharmacokinetics.

Authors:  Donald J Irby; Mustafa E Ibrahim; Anees M Dauki; Mohamed A Badawi; Sílvia M Illamola; Mingqing Chen; Yuhuan Wang; Xiaoxi Liu; Mitch A Phelps; Diane R Mould
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.